Clover Health Investments Corp. Class A (CLOV)

Over the past six months, Clover Health's stock price has experienced fluctuations. As of January 9, 2026, the share price was $2.60, representing a decline of 30.11% over the past year. More recently, the stock decreased by 2.22% in the past month and was down 0.79% on December 26, 2025. The 52-week high for the stock was $4.87, and the 52-week low was $2.12. In November 2025, Clover Health reported its third-quarter 2025 results, showing a 50% year-over-year revenue increase to $496.6 million, but also an increase in net losses to $24.4 million. Following this earnings report, shares in Clover Health fell by nearly 4%. The company also reported a medical loss ratio of 93.5% in Q3 2025, up from 82.8% in Q3 2024.

Demand for Clover Health's Medicare Advantage plans is influenced by the Annual Election Period (AEP) for Medicare, which typically runs from October 15 to December 7, with coverage starting on January 1 of the following year. This period is crucial for enrollment and membership growth. The company's strategic decisions regarding plan pricing, particularly during the AEP, can impact its membership numbers and financial outlook for the coming year. Clover Health also offers benefits like an Over-The-Counter (OTC) allowance and a LiveHealthy Rewards program, with OTC benefit amounts typically loaded quarterly and expiring if unused within the quarter, indicating a quarterly cycle for these specific benefits.

Clover Health Investments Corp. is a healthcare technology company focused on improving health outcomes for seniors through Medicare Advantage plans and proprietary technology. The company operates in the healthcare sector, providing Medicare Advantage insurance plans, including PPO and HMO plans, to Medicare-eligible individuals. The "Clover Assistant," a cloud-based software platform, utilizes machine learning to offer personalized insights and care recommendations to primary care providers, aiming to enable earlier detection and management of chronic diseases. Clover Health also operates as a direct contracting entity with the U.S. government.

Clover Health manages care for Medicare beneficiaries across 11 states. In 2020, the company planned to triple its geographic footprint, expanding its coverage to 108 counties in eight states, including new counties in Arizona, Georgia, New Jersey, Pennsylvania, South Carolina, Tennessee, and Texas, and entering Mississippi as a new market. Its corporate headquarters are located in Franklin, Tennessee, with additional offices in San Francisco, California, Jersey City, New Jersey, and Hong Kong.

In the past year, Clover Health has focused on demonstrating the effectiveness of its technology. In January 2026, the company highlighted positive clinical outcomes from its AI physician-enablement platform, Counterpart Assistant, including a significant increase in live third-party customer clinicians, an approximate 1,500 basis point Medical Care Ratio (MCR) differential for returning Clover members with Counterpart Assistant PCPs, and its PPO Medicare Advantage plan achieving the #1 HEDIS score nationwide for a second consecutive year. Historically, in February 2021, a short-seller report from Hindenburg Research alleged that Clover Health was under investigation by the Department of Justice and had failed to disclose this before going public, leading to a 12% drop in share prices.

Clover Health Investments Corp. has a diverse ownership structure, with a significant base of individual investors, alongside institutional funds and company insiders. Retail investors collectively hold the largest share, with 50% ownership, while institutional ownership accounts for 29% of the company. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Geode Capital Management, Llc, State Street Corp, Renaissance Technologies Llc, Pnc Financial Services Group, Inc., and Charles Schwab Investment Management Inc. Key individual owners (insiders) include Vivek Garipalli, Chamath Palihapitiya, Ian Osborne, Andrew Toy, Peter J. Kuipers and Scott J. Leffler.